C2 PHARMA (C2P) has expanded its portfolio of APIs and botanical extracts throughout 2020 and will continue pursuing the expansion into 2021. Multiple regulatory filings have been submitted to expand distribution channels globally across China, Taiwan, South Korea, Brazil, and Mexico.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“Since announcing our intentions to go through a growth spurt at CPhI Worldwide in 2019 we have been actively working to deliver on these promises with a range of regulatory filings. Our goal is to be a reliable, quality focused partner for ophthalmic pharmaceutical companies”, said Andrew Badrot, CEO of C2 PHARMA. “I am proud of our team and what we are accomplishing for our customers. In less than seven years from being founded, C2P has established an API portfolio with over ten US-DMF and CEP filed in addition to all the local filings we are announcing today, and we have been able to maintain operational excellence and expand our portfolio amid the COVID-19 pandemic”.